Navigation Links
No More Needles? Georgetown University Teams with Gentag and SAIC to Develop New Glucose Sensor Technology with Wireless Connection to Cell Phones
Date:6/18/2008

p>

About Georgetown University

Georgetown University is the oldest and largest Catholic and Jesuit university in America, founded in 1789 by Archbishop John Carroll. Georgetown today is a major student-centered, international, research university offering respected undergraduate, graduate and professional programs in Washington, DC, Doha, Qatar and around the world. For more information about Georgetown University, visit http://www.georgetown.edu.

Additional Links

http://otc.georgetown.edu Office of Technology Commercialization at Georgetown University

http://www.gentag.com/ Gentag, Inc.

http://www.saic.com/ Science Applications International Corporation (SAIC)

http://www1.georgetown.edu/college/research/molecules/14886.html

Georgetown Advanced Electronics Laboratory (GAEL)


'/>"/>
SOURCE Georgetown University; Gentag, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Georgetown researchers find stem cell marker controls 2 key cancer pathways
2. Georgetown U student selected for prestigious Bouchet Society
3. Georgetown leads major effort to combat disparities in DC stroke care
4. New USAID grant helps Georgetown meet unmet family planning needs worldwide
5. Hebrew University research on octopuses sheds light on memory
6. Gesture interface device developed by Ben-Gurion University of the Negev
7. $10 million gift will retain and recruit world-class researchers to University at Buffalo
8. The University of Arizona Program in Integrative Medicine Earns Center of Excellence Designation
9. Nursing Entrepreneur Whose Business Career Was Spurred by Venture Training is Honored with Alumna Award from Case Western Reserve University
10. Duke University Health System to Implement Clinically Optimized, Advanced Authentication Solution From Sentillion
11. Canine Cancer Web Exclusive for Dog Owners and Lovers, Presented by Morris Animal Foundation - Features Colorado State and Cornell University Veterinary Cancer Experts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/8/2009)... SAN FRANCISCO, Jan. 8 M... that David Hung, M.D., president and chief,execu... Morgan Healthcare,Conference on Wednesday, Janua...t. Francis Hotel in San Francisco. , Dr. Hu...clinical,development programs for Dimebon for Alz...
(Date:1/8/2009)...HINGTON, Jan. 8 The Pew...son has been named director, chemical and food saf...olicy program. Olson, who was formerly deputy staf...ttee on Environment and Public Works, brings nearl...nd consumer advocacy to Pew. , , "We are excit...
(Date:1/8/2009)...ould be used when assessing traditional risk facto...althDay News) -- Two molecular signs -- or "biomar...ation when trying to assess a person,s risk of str... or very low risk, adding these markers does not c...ay Nambi, a cardiologist at the Methodist DeBakey ...
(Date:1/8/2009)...hy Tune Promoted to Principal. Christine Siu and ..., MINNEAPOLIS, SAN FRANCISCO and STAMFORD, Conn.,...tners, a health care venture capital firm that inv...ies, today announced the promotion of three member...moted to Principal. Christine Siu and Jason Brown...
Breaking Medicine News(10 mins):Health News:Medivation Announces Participation in 27th Annual J.P. Morgan Healthcare Conference 2Health News:Veteran Environmental Health Expert Erik D. Olson to Join Pew 2Health News:Inflammation Markers May Help Predict Stroke Risk 2Health News:Inflammation Markers May Help Predict Stroke Risk 3Health News:Thomas, McNerney & Partners Promotes Three Members of Its Investment Team 2
... to findings of a recent study , 70 percent of all... ill individuals.// Researchers studied nearly 43,...p homes to explore the correlation between patient...nd drug use. Results showed 28 percent of patients...
...rs now say they’ve found one drug that may success...cer.// In a study of 22 patients with breast, pros...42 percent had their tumors either stabilize or sh...y , it turns off one of the switches within the ca...
...of a new study shows that high-doses of vitamin E...erall risk of early death.// Vitamin E is one of ...wth and function. On average, dietary intake of vi...y. Other sources of the vitamin include wheat germ...
...rs say there may be a new way to correct hard-to-t...g during a minimally // invasive surgical procedur...ure a more complete correction. Birthmarks basica...le with the birthmarks do not experience problems,...
Other Medicine News:
(Date:1/6/2009)...swire-FirstCall/ -- , - Early Renewal of th...ember 2011 , - Expansion of the Scope of th...Ophthalmology , - Revised Commercial Terms ...o a Third Party , ExonHit Therapeutics (A...of its existing drug discovery collaboration with ...
(Date:12/30/2008)...ewswire/ -- The Coalition for 21st Century Medicin...enentech, Inc. on December 5, 2008, seeking to res...tic tests to physicians and patients. The request...arm patient care and rests on flawed scientific an...s to encourage the research, development, and comm...
(Date:12/17/2008)...t and validation of non-animal alternative test me...re/ -- MatTek Corporation today announced that the...ed the scientific validity of the Modified EpiDerm...g. ESAC concluded that the Modified EpiDerm SIT h...diction of skin irritating and non-irritating test...
(Date:12/17/2008)...l/ -- Delcath Systems, Inc. (Nasdaq: DCTH ) toda...h.D., to Delcath,s Board of Directors. Dr. Contag...perience working with international and domestic i....com/cgi-bin/prnh/20081118/NY46990LOGO ) , ,... 2006 and served as CEO. Prior to starting Cobalt...
Breaking Medicine Technology:ExonHit Therapeutics Expands Strategic Collaboration With Allergan 2ExonHit Therapeutics Expands Strategic Collaboration With Allergan 3ExonHit Therapeutics Expands Strategic Collaboration With Allergan 4Coalition for 21st Century Medicine Issues Statement in Opposition of Genentech Petition to Restrict Lab Use of Diagnostic Tests for Physicians and Patients 2Coalition for 21st Century Medicine Issues Statement in Opposition of Genentech Petition to Restrict Lab Use of Diagnostic Tests for Physicians and Patients 3Coalition for 21st Century Medicine Issues Statement in Opposition of Genentech Petition to Restrict Lab Use of Diagnostic Tests for Physicians and Patients 4EpiDerm's Skin Irritation Test Fully Validated in European Union 2Delcath Adds Dr. Pamela R. Contag to Its Board of Directors 2Delcath Adds Dr. Pamela R. Contag to Its Board of Directors 3Dragon retains leading investor relations firm 3999 1Dragon retains leading investor relations firm 3999 2Dragon retains leading investor relations firm 3999 3QuoNova Global Executive Appointments 3994 1QuoNova Global Executive Appointments 3994 2QuoNova Global Executive Appointments 3994 3QuoNova Global Executive Appointments 3994 4Fludarabine Mitoxantrone and Zevalin 28R 29 Produces 96 25 Complete Remission Rate in First Line Treatment of Patients with Follicular Non Hodgkins L 1531 1Fludarabine Mitoxantrone and Zevalin 28R 29 Produces 96 25 Complete Remission Rate in First Line Treatment of Patients with Follicular Non Hodgkins L 1531 2Fludarabine Mitoxantrone and Zevalin 28R 29 Produces 96 25 Complete Remission Rate in First Line Treatment of Patients with Follicular Non Hodgkins L 1531 3Fludarabine Mitoxantrone and Zevalin 28R 29 Produces 96 25 Complete Remission Rate in First Line Treatment of Patients with Follicular Non Hodgkins L 1531 4New Brain Fitness Training Promotes Health and Independence of Long Term Care Insurance Policyholders 14470 1New Brain Fitness Training Promotes Health and Independence of Long Term Care Insurance Policyholders 14470 2New Brain Fitness Training Promotes Health and Independence of Long Term Care Insurance Policyholders 14470 3
...ries, Inc. Today,Announced the Top Line Results of...) Study with the Compound Desmoteplase , Aachen (G...k,Exchange, Prime Standard: PA8) and its US partne...unced topline results of,the DIAS-2 (Desmoteplase ...Desmoteplase. The Phase III study was designed to,...
...tCall/ - Research,collaborators with Oncolytics Bi... a poster presentation covering REOLYSIN(R),clinic...Oncology,(ASCO) Annual Meeting, to be held June 1-...f Oncolytics, U.K. Phase I systemic,administration... Phase I Study of,Wild-Type Oncolytic Reovirus Adm...
Other Medicine Technology:Top Line Results of Phase III Study in Acute Ischemic Stroke,(DIAS-2) Do Not Demonstrate Difference Between Desmoteplase and,Placebo 2Top Line Results of Phase III Study in Acute Ischemic Stroke,(DIAS-2) Do Not Demonstrate Difference Between Desmoteplase and,Placebo 3Top Line Results of Phase III Study in Acute Ischemic Stroke,(DIAS-2) Do Not Demonstrate Difference Between Desmoteplase and,Placebo 4Oncolytics Biotech Inc.'s Research Collaborators to Present,REOLYSIN Clinical Trial Data at ASCO Conference 2
...aboratory and a worldwide leader in innovative lab...xtensive test menu of highly complex and unique me...ned by the University of Utah, ARUP Laboratories' ...versity teaching hospitals and children's hospital...
...aboratory and a worldwide leader in innovative lab...xtensive test menu of highly complex and unique me...ned by the University of Utah, ARUP Laboratories' ...versity teaching hospitals and children's hospital...
...aboratory and a worldwide leader in innovative lab...xtensive test menu of highly complex and unique me...ned by the University of Utah, ARUP Laboratories' ...versity teaching hospitals and children's hospital...
...aboratory and a worldwide leader in innovative lab...xtensive test menu of highly complex and unique me...ned by the University of Utah, ARUP Laboratories' ...versity teaching hospitals and children's hospital...
Medicine Products: